| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
|
Lancet Oncol
|
2006
|
8.53
|
|
2
|
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.
|
Blood
|
2004
|
4.05
|
|
3
|
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
|
Blood
|
2007
|
3.05
|
|
4
|
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
|
Lancet Oncol
|
2011
|
2.87
|
|
5
|
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
|
Lancet Oncol
|
2008
|
2.34
|
|
6
|
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
|
Blood
|
2008
|
2.17
|
|
7
|
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
|
Blood
|
2008
|
2.14
|
|
8
|
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
|
Blood
|
2009
|
1.84
|
|
9
|
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
|
J Clin Oncol
|
2005
|
1.83
|
|
10
|
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
|
Lancet Oncol
|
2011
|
1.81
|
|
11
|
Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
|
Blood
|
2002
|
1.43
|
|
12
|
Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
|
Pol Arch Med Wewn
|
2015
|
1.41
|
|
13
|
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
|
J Clin Oncol
|
2014
|
1.10
|
|
14
|
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study.
|
Br J Haematol
|
2010
|
0.87
|
|
15
|
Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.
|
Tumour Biol
|
2012
|
0.86
|
|
16
|
Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.
|
Med Oncol
|
2010
|
0.84
|
|
17
|
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients.
|
Med Oncol
|
2012
|
0.84
|
|
18
|
Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.
|
Med Oncol
|
2011
|
0.82
|
|
19
|
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
|
Leuk Lymphoma
|
2011
|
0.81
|
|
20
|
Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients.
|
Ann Transplant
|
2013
|
0.81
|
|
21
|
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
|
Clin Pharmacokinet
|
2011
|
0.80
|
|
22
|
Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.
|
J Clin Immunol
|
2007
|
0.80
|
|
23
|
FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2011
|
0.80
|
|
24
|
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
|
J Hematol Oncol
|
2012
|
0.80
|
|
25
|
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.
|
Clin Drug Investig
|
2009
|
0.78
|
|
26
|
Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma.
|
Cancer Genet Cytogenet
|
2005
|
0.78
|
|
27
|
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.78
|
|
28
|
Unusual IgD+/CD38-follicular lymphoma with leukemic presentation.
|
Med Oncol
|
2006
|
0.78
|
|
29
|
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.
|
Leuk Lymphoma
|
2013
|
0.77
|
|
30
|
Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
31
|
A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival.
|
Med Oncol
|
2009
|
0.77
|
|
32
|
Mantle cell lymphoma presenting with paraproteinemia.
|
Med Oncol
|
2005
|
0.77
|
|
33
|
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
|
Cancer
|
2008
|
0.77
|
|
34
|
Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
|
Am J Ther
|
2016
|
0.76
|
|
35
|
Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
|
Clin Biochem
|
2010
|
0.75
|
|
36
|
miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
|
Tumour Biol
|
2015
|
0.75
|
|
37
|
Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.
|
Ann Hematol
|
2013
|
0.75
|
|
38
|
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
|
Chemotherapy
|
2014
|
0.75
|
|
39
|
Usefulness of real-time PCR in long-term follow-up of follicular lymphoma patients.
|
Acta Biochim Pol
|
2007
|
0.75
|
|
40
|
Unusual cyclin D1 positive marginal zone lymphoma of mediastinum.
|
Med Oncol
|
2006
|
0.75
|
|
41
|
Developing a European network for adult ALL.
|
Hematol J
|
2004
|
0.75
|
|
42
|
[Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group].
|
Pol Arch Med Wewn
|
2003
|
0.75
|